search button

Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma

  • Authors:
    • Maiko Yoshida
    • Hiroyuki Ogino
    • Hiromitsu Iwata
    • Yukiko Hattori
    • Shingo Hashimoto
    • Koichiro Nakajima
    • Shigeru Sasaki
    • Masaki Hara
    • Yoshitaka Sekido
    • Jun‑Etsu Mizoe
    • Yuta Shibamoto

  • View Affiliations

  • Published online on: January 11, 2019     https://doi.org/10.3892/ol.2019.9922
  • Pages: 3026-3034
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Transient increases in α‑fetoprotein (AFP) and protein induced by vitamin K antagonist II (PIVKA‑II), so‑called flares, are frequently observed after treatment of hepatocellular carcinoma (HCC). In the present study, changes in AFP and PIVKA‑II levels after proton therapy (PT), and the relationship between the flare phenomenon and clinical response were investigated. In 82 patients with stage I/II HCC (59 with no recurrence and 23 with out‑of‑field recurrence within 1 year), serum AFP and PIVKA‑II levels were measured at 1, 3, 6, 9 and 12 months post‑PT. AFP and PIVKA‑II flares were defined as a >20% increase from the preceding serum level above 20 ng/ml (AFP) or 40 mAU/ml (PIVKA‑II), followed by a >20% drop. Among the 59 patients with no recurrence, 3 (5.1%) had an AFP flare, while 23 (39%) had a PIVKA‑II flare. The median time to AFP and PIVKA‑II flare peaks was 1 and 6 months, respectively. In 4 patients, PIVKA‑II flares were observed twice during follow‑up. In 1 patient, AFP and PIVKA‑II flares were observed simultaneously at 1 month post‑PT. The PIVKA‑II level pre‑PT was significantly higher in the PIVKA‑II flare‑positive group compared with that in the flare‑negative group (P=0.015, odds ratio 4.3, 95% confidence interval, 1.3‑14.0). In the 23 patients with out‑of‑field recurrence, the median increase rate of PIVKA‑II (203%) was higher than that in the PIVKA‑II‑flare‑positive group (111%, P=0.035) and the time to recurrence (median, 9 months) was longer than the time to peak AFP level (1 month) in the AFP‑flare‑positive group (P=0.033). There was no significant association between flares and clinical response. Increases in AFP and PIVKA‑II levels following PT should be assessed with caution to avoid misinterpretation of therapeutic outcome.
View Figures
View References

Related Articles

Journal Cover

March-2019
Volume 17 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yoshida M, Ogino H, Iwata H, Hattori Y, Hashimoto S, Nakajima K, Sasaki S, Hara M, Sekido Y, Mizoe JE, Mizoe JE, et al: Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. Oncol Lett 17: 3026-3034, 2019
APA
Yoshida, M., Ogino, H., Iwata, H., Hattori, Y., Hashimoto, S., Nakajima, K. ... Shibamoto, Y. (2019). Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma. Oncology Letters, 17, 3026-3034. https://doi.org/10.3892/ol.2019.9922
MLA
Yoshida, M., Ogino, H., Iwata, H., Hattori, Y., Hashimoto, S., Nakajima, K., Sasaki, S., Hara, M., Sekido, Y., Mizoe, J., Shibamoto, Y."Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma". Oncology Letters 17.3 (2019): 3026-3034.
Chicago
Yoshida, M., Ogino, H., Iwata, H., Hattori, Y., Hashimoto, S., Nakajima, K., Sasaki, S., Hara, M., Sekido, Y., Mizoe, J., Shibamoto, Y."Transient increases in serum α fetoprotein and protein induced by vitamin K antagonist II levels following proton therapy does not necessarily indicate progression of hepatocellular carcinoma". Oncology Letters 17, no. 3 (2019): 3026-3034. https://doi.org/10.3892/ol.2019.9922